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Abstract
To shed light on the efficacy of oxygen therapy in pulmonary arterial hypertension (PAH) when hypoxemia is not present, we
report seven years of observational data for a female patient recorded between February 2012 and February 2019 when she was
aged 7.8–14.8 years. The patient was born with an atrial septal defect (closed spontaneously at 2.3 years) and ventricular septal
defect (surgically repaired at 8.3 years) and then diagnosed with PAH at 8.9 years . The patient was prescribed bosentan soon after
diagnosis and for the next 4.8 years, during which a first phase of oxygen therapy (nocturnal) was trialed for 2.8 years. Mean
pulmonary arterial pressure (mPAP) and systolic PAP (sPAP) remained stable and at mild levels when oxygen was administered, but
then increased progressively to severe levels over two years without oxygen. This coincided with worsening right ventricular
pathology during the later part of this period without oxygen. Re-initiation of more intensive oxygen therapy while the patient was
still on bosentan and before pharmocotherapy was changed coincided with a large and rapid fall in sPAP, confirmed by right heart
catheterization measurements of mPAP. During this entire observation period, the patient remained normoxemic. These obser-
vations challenge the notion that oxygen therapy should be restricted to patients with hypoxemia and strengthen calls for further
study of oxygen therapy in PAH.
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Case description
To shed light on the efficacy of oxygen therapy in pulmon-
ary arterial hypertension (PAH) when hypoxemia is not
present, we report seven years of observational data
for a female patient recorded between February 2012 and
February 2019 when she was aged 7.8–14.8 years. The
patient provided permission to write and publish this
report after it was described and read by her.
Early history and PAH diagnosis
The patient was born at 980m above sea level in May 2004;
she lived at this altitude for 2.9 years before relocating to
lower locations (<300m) thereafter. She was born with a
large atrial septal defect (ASD) and moderate ventricular
septal defect (VSD). Four weeks after birth, there was mild
cardiomegaly and increased pulmonary vascularity (CXR).
During early childhood, she exhibited exertional breathless-
ness and expiratory grunting. The ASD closed spontaneously
by 2.3 years and the VSD was surgically closed at 8.3 years.
Seven months later, in April 2013, right heart catheterization
(RHC) measurements confirmed PAH (mPAP already
defined in the Abstract mPAP¼ 40mmHg, pulmonary capil-
lary wedge pressure¼ 9mmHg).
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A sleep study performed two months after PAH diagno-
sis showed no evidence of sleep-disordered breathing
(oxygen saturation¼ 93–97%) or obstructive sleep apnea.
Lung function was assessed at 9.8 years; standard indices
(FVC, FEV, FEV1) were normal, but diffusion capacity
(DLCO¼ 71% normal) was decreased and percentage of
residual volume to total lung capacity (30%) was increased.
Chest CT scans at 9.8 and 10.0 years did not reveal pulmon-
ary embolism, focal lesions, or pleural effusion. There were
no distinctive signs, symptoms, or risk factors for pulmon-
ary embolism during the rest of the study period.
Pharmacotherapy
The patient began L-arginine (1.5 g daily) 10 days after PAH
diagnosis. Ten days later, bosentan (62.5mg daily) was
introduced and the dose was doubled (125mg daily) after
one month and doubled again in February 2014 (250mg
daily). This treatment continued until 19 November 2018
when bosentan was replaced with macitentan (10mg daily)
and tadalafil (20mg daily increased to 40mg daily after
two weeks).
Oxygen therapy
The patient engaged in oxygen therapy in two distinct
phases. Phase-1 nocturnal-only oxygen therapy started in
late May 2013. This phase was beset with difficulties
(humidification, nasal discomfort, nasal congestion, device
alarming, poor patient motivation linked to clinician dis-
couragement) and characterized by intermittency. For the
first seven months, 90% oxygen was delivered as 30-mL
pulses/breath via nasal prongs using a portable oxygen con-
centrator for 4–8 h, 2–5 times per week. Later, a continuous
oxygen concentrator delivering 90% oxygen via nasal
prongs at 2L.min–1 was used, sometimes with an add-on
air warmer-humidifier, again only for 4–8 h, 2–5 times per
week. Based on resting measurements of expired minute
ventilation in this patient (5 L.min–1), the FiO2 associated
with continuous O2 delivery was 0.5. The patient experi-
enced frequent colds in mid-2015 resulting in a six-month
interruption to therapy. Phase-1 stopped in December 2016
following prolonged nasal congestion and technical prob-
lems. Phase-2 started in late 2018 in an intensive way.
Daytime therapy (30-mL pulse mode, 90% O2) began on
26 October with the dose increasing over two weeks from
2–3 h daily to 5–9 h daily. Nocturnal therapy (continuous
flow, 2L.min–1, 8–10 h daily) started on 11 November, fol-
lowing humidification troubleshooting, and is proceeding
well to date due to strong patient engagement.
Pulmonary hemodynamics
Systolic pulmonary arterial pressure (sPAP) was measured
by RHC or estimated by echocardiographic measurement of
tricuspid regurgitant jet velocity (4v2þ 10). Twenty-two sPAP
measurements are reported (Fig. 1) along with other RHC
measurements, arterial oxygen saturation, weight, and height.
There was no evidence of residual shunts during RHCs.
Fig. 1. Pulmonary hemodynamic and systemic arterial responses
during a seven-year period of growth from childhood to adolescence in
a female patient with PAH. Oxygen therapy is indicated by light grey
shading (phase 1) and dark gray shading (phase 2). sPAP, systolic pul-
monary arterial pressure; mPAP, mean pulmonary arterial pressure;
PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure;
MAP, mean arterial pressure; CO, cardiac output; PVR, pulmonary
vascular resistance; %SaO2, percent oxygen saturation of hemoglobin
in arterial blood.
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From December 2016 to October 2018, there was a 75 %
increase in mean PAP (mPAP) to severe levels (Fig. 1). This
coincided with increased limb edema and exertional breath-
lessness, diagnosis of vocal cord palsy (inactive left recurrent
laryngeal nerve), and two episodes of gastritis treated suc-
cessfully. Echocardiographic measurements (six-monthly
intervals) showed an abrupt increase in right ventricular
end-diastolic diameter (10%) and decrease in TAPSE
(17%) from April to October 2018. NT-proBNP levels
were normal in this late period (77–101 ng.mL–1). Six-
minute walk distance (6MWD) peaked in October 2018
(603m, age¼ 14.4 years) after a gradual rise from initial
measurements at 8–9 years (450–475m).
Discussion
Current guidelines do not recommend oxygen therapy as a
PAH treatment, unless patients develop hypoxemia.1 This
view is based on a lack of RCT evidence and a study of
Eisenmenger patients who were severely hypoxemic but
did not benefit from treatment.2 There is, however, other
evidence of improvements in pulmonary hemodynamics,
fitness, and survival with oxygen therapy,3–5 although the
relevance of hypoxemia is not clear. This case report pro-
vides evidence of significant benefit from oxygen therapy in
the absence of hypoxemia.
The clinical history and sPAP data (Fig. 1) suggest early
development of pulmonary vasculopathy before heart sur-
gery and PAH associated with congenital heart disease,
rather than of idiopathic or surgical origin. After initiation
of bosentan and phase-1 oxygen therapy, pulmonary arterial
pressures (PAPs) stabilized for three years at a level indica-
tive of mild PAH. A temporary spike in sPAP coincided
with interruption to oxygen therapy, suggesting that
phase-1 therapy helped stabilize pulmonary pressures des-
pite the intermittency of therapy.
Following the cessation of phase-1 oxygen therapy, there
was a progressive increase in sPAP and mPAP over two
years to levels consistent with severe PAH. This was asso-
ciated with worsening signs, symptoms, and right ventricu-
lar pathology later during this period; whereas 6MWD
peaked at this point, raising questions about its clinical util-
ity in treating a young patient. The worsening scenario
prompted the initiation of the intensive phase-2 oxygen ther-
apy (day and night) while the patient was still on bosentan
and several weeks before pharmacotherapy was altered. Re-
initiation of oxygen therapy coincided with improvements in
signs and symptoms and a rapid fall in sPAP, verified imme-
diately before pharmacotherapy was changed, towards
levels observed two years earlier. RHC measurements con-
firmed the large and rapid reversal in pulmonary pressures,
due to a reduction in pulmonary vascular resistance given
that cardiac output did not change. These data suggest that
oxygen acted as a rapid and potent pulmonary vasodilator,
halted the rise in pulmonary pressures, and contributed sub-
stantially to the reversal in mPAP.
During the entire study, the patient remained normoxe-
mic (Fig. 1). The benefits of oxygen therapy for this patient
are consistent with improvements in pulmonary hemo-
dynamics during acute oxygen testing in normoxemic
patients6 and long-term survival benefit in a pediatric popu-
lation which included patients who were normoxemic before
therapy.3 These observations challenge the notion that
oxygen therapy should be restricted to patients with hypox-
emia and strengthen calls for further study of oxygen ther-
apy in PAH.3,5
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